| Intrinsic Valuation of: AUROPHARMA | |||||||||||
| Free Cash Flow Average and Growth over past 5Y | Key Statistics | ||||||||||
| Year | FCF | FCF (FCF/Revenue) | |||||||||
| 2020 | - | - | EPS (FY) | 60 | Market Cap | ₹659B | |||||
| 2021 | - | - (-) | P/E Ratio | 19 | Total Asset | ₹498B | |||||
| 2022 | ₹23B | - (-) | Net Income | ₹38B | Total Debt | ₹16B | |||||
| 2023 | ₹-3B | -114.4% (-113.7%) | EBITDA | ₹70B | Total Liab | ₹171B | |||||
| 2024 | ₹-11B | -237.8% (-189.7%) | Opr Margin | 0.16 | Debt/Equity | 0.05 | |||||
| 2025 | ₹14B | 224.7% (214.1%) | PreTax Margin | 14.34 | BV/Share | 489 | |||||
| 5Y Average FCF | ₹6B | -42.5% (-29.8%) | |||||||||
| Overall Market Assumptions: | |||||||||||
| Assumptions: | P/E for No-Growth Company: | 7.0 | |||||||||
| Perpetual Growth Rate (g): | 2.5% | Historical US Bond Yield: | 4.4% | ||||||||
| Discount Rate (WACC): | 7.4% | Current US Bond Yield: | 3.5% | ||||||||
| Forcasting Future Free Cash Flow for next 6Y | Modified Benjamin Graham's Intrinsic Value | ||||||||||
| Year | FCF Projection (4.0%) | ||||||||||
| 2026 | ₹15B | MBG Intrinsic Value | ₹535 | ||||||||
| 2027 | ₹15B | ||||||||||
| 2028 | ₹16B | ||||||||||
| 2029 | ₹16B | ||||||||||
| 2030 | ₹17B | ||||||||||
| 2031 | ₹18B | ||||||||||
| Terminal Value | ₹370B | Net Worth/Share | ₹562 | ||||||||
| DCF Valuation | DCF Valuation "What If" Scenario Table | ||||||||||
| Enterprise Value | ₹316B | Growth Rate | |||||||||
| (+) Cash & Cash Equivalents | ₹56B | ₹613 | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% | ||||
| (-) Total Debt | ₹16B | WACC | 7.3% | 548 | 582 | 624 | 675 | 740 | |||
| Equity Value | ₹356B | 7.4% | 544 | 578 | 618 | 669 | 732 | ||||
| Shares Outstanding | 580,801,984 | 7.4% | 540 | 573 | 613 | 662 | 723 | ||||
| 7.9% | 502 | 530 | 562 | 601 | 649 | ||||||
| DCF Intrinsic Value | ₹613 | 8.4% | 471 | 494 | 520 | 552 | 590 | ||||
| Analyzed by QuantJuice (2025) | |||||||||||